Iodine I 131 Monoclonal Antibody TNT-1/B in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed glioblastoma multiforme
• * Focal disease
• * Progressive or recurrent disease after prior treatment with radiotherapy and/or chemotherapy
• * Low-grade astrocytoma that progressed to glioblastoma multiforme after prior radiotherapy and/or chemotherapy allowed
• Gross tumor volume 5-60 mL
• No intraventricular tumor, infratentorial tumor, or tumor that communicates with the ventricles
• No bilateral non-contiguous gadolinium-enhancing tumor
• No diffuse disease, defined as any satellite lesion \> 1.5 cm from the anticipated location of a catheter tip OR \> 2 satellite lesions
• No ventricular invasion outside the anticipated radiotherapy volume
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• Karnofsky 60-100%
• Life expectancy
• Not specified
• Hematopoietic
• Absolute neutrophil count ≥ 1,500/mm\^3
• Platelet count ≥ 100,000/mm\^3
• Hemoglobin ≥ 9.0 g/dL
• Hepatic
• Bilirubin ≤ 1.5 mg/dL
• AST and ALT ≤ 2.5 times upper limit of normal (ULN)
• Hepatitis B negative
• No evidence of active hepatitis
• Renal
• Creatinine ≤ 1.7 mg/dL
• BUN ≤ 2 times ULN
• Cardiovascular
• No uncontrolled hypertension
• No unstable angina pectoris
• No uncontrolled cardiac dysrhythmia
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• Able to undergo MRI
• Mini Mental State Exam score ≥ 15
• No serious infection
• No other medical illness that would preclude study participation
• No other malignancy within the past 5 years except curatively treated carcinoma in situ or basal cell skin cancer
• No psychological or sociological condition, addictive disorder, or other condition that would preclude study compliance
• No known or suspected allergy to study drug or iodine
• No known HIV positivity
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• No prior monoclonal antibodies
• No prior local immunotherapy or treatment with the following biologic agents:
• * Immunotoxins
• * Immunoconjugates
• * Antiangiogenesis compounds
• * Antisense agents
• * Peptide receptor antagonist
• * Interferons
• * Interleukins
• * Tumor infiltrating lymphocytes
• * Lymphokine-activated killer cells
• * Gene therapy
• Chemotherapy
• See Disease Characteristics
• At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)
• At least 3 months since prior polifeprosan 20 with carmustine implant (Gliadel wafer\^® )
• Endocrine therapy
• Must be maintained on a stable corticosteroid dose (approximately 4 mg) for ≥ 2 weeks before study entry
• Radiotherapy
• See Disease Characteristics
• At least 3 months since prior radiotherapy
• No prior brachytherapy or radiosurgery
• Surgery
• At least 4 weeks since prior surgery
• Other
• Recovered from all prior therapy
• At least 1 month since prior investigational agents
• No more than 2 prior treatment regimens
• No other prior local therapy